<DOC>
	<DOCNO>NCT00081614</DOCNO>
	<brief_summary>The primary purpose study assess potential benefit combine two targeted therapy ( anti-EGF inhibitor along anti-VEGF inhibitor ) . The goal determine whether addition Erlotinib Avastin improve benefit metastatic renal cell carcinoma ( RCC ) regard time progression , response rate , duration response , survival compare Avastin alone . Since Avastin show active renal cancer , goal ass whether activity enhance Erlotinib .</brief_summary>
	<brief_title>A Study Evaluating Tarceva Combination With Avastin Versus Avastin Alone Treating Metastatic Renal Cell Carcinoma</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Renal Cell</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Erlotinib Hydrochloride</mesh_term>
	<criteria>Written inform consent Histologically confirm RCC clear cell histology Confirmed metastatic RCC Age &gt; =18 year ECOG performance status 0 1 Life expectancy &gt; =3 month Prior nephrectomy Measurable disease , define RECIST Use acceptable mean contraception ( potentially fertile men woman ) RCC predominantly sarcomatoid feature Prior systemic adjuvant therapy RCC Prior radiotherapy RCC within 28 day prior Day 0 , exception single fraction radiotherapy give indication pain control Treatment Avastin , Tarceva , agent , either investigational market , act either EGFR inhibition antiangiogenesis mechanisms 24hour urine collection &gt; =1 g protein INR &gt; =1.5 , except subject receive warfarin therapy Serum creatinine &gt; 2.0 mg/dL Serum calcium &gt; 10 mg/dL ( correct ) Absolute neutrophil count ( ANC ) &lt; 1500/uL Platelet count &lt; 75,000/uL Total bilirubin &gt; 2.0 mg/dL AST ALT &gt; 5× upper limit normal ( ULN ) subject document liver metastasis ; &gt; 2.5 × ULN subject without evidence liver metastasis LDH &gt; 1.5× ULN Hemoglobin &lt; 9 gm/dL ( may transfuse receive epoetin alfa [ e.g. , Epogen ] maintain exceed level ) History serious systemic disease , include myocardial infarction within last 6 month , uncontrolled hypertension ( blood pressure &gt; 160/110 mmHg medication ) , unstable angina , New York Heart Association ( NYHA ) Grade II great congestive heart failure , unstable symptomatic arrhythmia require medication ( subject chronic atrial arrhythmia , i.e. , atrial fibrillation paroxysmal supraventricular tachycardia , eligible ) , Grade II great peripheral vascular disease History acute stroke within 6 month prior randomization Patients dialysis Other invasive malignancy , include bladder cancer lowgrade endometrial cancer , within 5 year randomization ( squamous basal cell carcinoma skin ) Pregnancy breast feed Inability comply study and/or followup procedure History disease , metabolic dysfunction , physical examination finding , clinical laboratory find give reasonable suspicion disease condition contraindicate use investigational drug might affect interpretation result study render subject high risk treatment complication Serious , nonhealing wound , ulcer , bone fracture Evidence bleed diathesis coagulopathy History clinical evidence central nervous system brain metastasis History bowel gastric perforation Major surgical procedure , open biopsy , significant traumatic injury within 28 day prior Day 0 , anticipation need major surgical procedure course study Fine needle aspiration core biopsy within 7 day prior Day 0</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2014</verification_date>
	<keyword>Metastatic renal cell carcinoma</keyword>
</DOC>